De-risking drug development: Key chemistry, manufacturing, and controls (CMC) and physiologically based pharmacokinetic (PBPK) approaches in early development Blog 降低药物开发风险:早期开发中的关键化学、制造和控制(CMC)及基于生理的药代动力学(PBPK)方法 2024 年 11 月 22 日 In drug development, early strategic planning is crucial to minimizing risks, optimizing…Certara2024 年 11 月 22 日
Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen Poster 增强型确定性筛选设计为 CAR-T 细胞和淋巴清除疗法的 1 期筛选提供了高效率 Certara2024 年 11 月 22 日
Oncology MIDD Simulator, A User-Friendly Application for Overall Survival Forecasting in Early Oncology Trials Poster Oncology MIDD Simulator — 用于早期肿瘤学试验总生存期预测的用户友好型应用程序 Certara2024 年 11 月 22 日
Quantitative Systems Pharmacology model for combined targeting of BAFF and CD40 pathways in systemic lupus erythematosus Poster 系统性红斑狼疮中联合靶向 BAFF 和 CD40 通路的定量系统药理学模型 Certara2024 年 11 月 22 日
Population pharmacokinetic modeling of niraparib to assess different absorption models Poster 尼拉帕利(Niraparib)群体药代动力学建模以评估不同吸收模型 Certara2024 年 11 月 22 日
Efficient Phase 1 Selection of CAR-T and Lymphodepletion Regimens Using Augmented Definitive Screening Design Poster Efficient Phase 1 Selection of CAR-T and Lymphodepletion Regimens Using Augmented Definitive Screening Design How an augmented definitive screening design identified CAR-T and lymphodepletion regimens with 2.37-fold higher odds…Certara2024 年 11 月 20 日
Population Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors Publication Population Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors Find out how PopPK modelling supports precise tamibarotene dosing in pediatric and young adult solid…Certara2024 年 11 月 14 日
Why clinical pharmacology & pharmacometrics should collaborate Blog 临床药理学与定量药理学为何要合作 A symbiosis between a modeler and a trialist is often required to develop a model-informed…Certara2024 年 11 月 8 日
A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population Publication Zilovertamab Vedotin 在血液恶性肿瘤患者中的序贯群体药代动力学模型推断至儿童群体 Certara2024 年 11 月 7 日